We evaluated a 33 year-old gentleman for peripheral blood stem cell donation for an unrelated recipient. Evaluation at that time was significant for obesity. He was not on any medications. His laboratory evaluation revealed normal complete blood count with WBC of 7500/mL, Hb of 16.1 g/dL and platelet count of 352 000/mL. He was cleared to donate and was mobilized with G-CSF with a dose of 10 mcg/kg daily for 5 days. On the fifth day, his WBC was 38 600/mL, platelet count of 368 000/mL, Hb of 15.3 g/dL and absolute CD34 þ cell count of 208 cells/mL. A total of 169.72 Â 10 7 CD34 þ cells were collected and sent to the unrelated recipient. The donor had no unusual events related to the donation and was fully recovered 2 weeks after donation. He was well until 9 months post-donation, when he developed sinusitis that was treated with a short course of oral antibiotics. After 4 weeks, he presented to his local physician with petechiae and his laboratory evaluation revealed a WBC 400/mL, ANC of o200/mL, platelet count of 4000/mL and a Hb of 9 g/dL. BM biopsy revealed markedly hypocellular BM with trilineage hypoplasia with normal male karyotype on cytogenetic analysis. Fluorescence in-situ hybridization for myelodysplastic syndrome-associated abnormalities failed to detect any cytogenetic abnormalities. Flow cytometry did not show evidence of paroxysmal nocturnal hemoglobinuria. As the patient remained transfusion dependent and he did not have any HLA identical siblings, he was started on immune suppression with cyclosporine and antithymocyte globulin as has been previously described.
We evaluated a 33 year-old gentleman for peripheral blood stem cell donation for an unrelated recipient. Evaluation at that time was significant for obesity. He was not on any medications. His laboratory evaluation revealed normal complete blood count with WBC of 7500/mL, Hb of 16.1 g/dL and platelet count of 352 000/mL. He was cleared to donate and was mobilized with G-CSF with a dose of 10 mcg/kg daily for 5 days. On the fifth day, his WBC was 38 600/mL, platelet count of 368 000/mL, Hb of 15.3 g/dL and absolute CD34 þ cell count of 208 cells/mL. A total of 169.72 Â 10 7 CD34 þ cells were collected and sent to the unrelated recipient. The donor had no unusual events related to the donation and was fully recovered 2 weeks after donation. He was well until 9 months post-donation, when he developed sinusitis that was treated with a short course of oral antibiotics. After 4 weeks, he presented to his local physician with petechiae and his laboratory evaluation revealed a WBC 400/mL, ANC of o200/mL, platelet count of 4000/mL and a Hb of 9 g/dL. BM biopsy revealed markedly hypocellular BM with trilineage hypoplasia with normal male karyotype on cytogenetic analysis. Fluorescence in-situ hybridization for myelodysplastic syndrome-associated abnormalities failed to detect any cytogenetic abnormalities. Flow cytometry did not show evidence of paroxysmal nocturnal hemoglobinuria. As the patient remained transfusion dependent and he did not have any HLA identical siblings, he was started on immune suppression with cyclosporine and antithymocyte globulin as has been previously described. 1 He remained transfusion-dependent 8 weeks following the initiation of immune suppression; contact was made with the National Marrow Donor Program (NMDP) to inquire if there were any PBSC left following the transplant of the recipient. The recipient was well engrafted and there were remaining unused CD34 þ cells stored at the recipient's transplant center. After consulting with the transplant center physicians and the recipient, 37.5 Â 10 7 cells were transferred back to our center.
After 3 months of the diagnosis of severe aplastic anemia and 1 year post-PBSC donation, the patient received cyclophosphamide 50 mg/kg daily for four doses followed by infusion of his autologous stem cells at a total dose 2.64 Â 10 6 /kg CD34 þ cells. He did well and has achieved neutrophil engraftment (ANC4500 for 3 days) and platelet engraftment on day þ 11 and þ 20, respectively, post-stem cell infusion. With a 4-month follow-up the patient is well engrafted and is transfusion independent.
In a recent report on 2408 PBSC donors by the NMDP in long-term follow-up, 2 none developed aplastic anemia. The cause of the severe aplastic anemia in our patient is not clear and is unlikely to be related to the PBSC donation and exposure to G-CSF. Because our patient as well as the recipient of the PBSC engrafted promptly, we believe that the injury to his marrow and stem cells developed at a later time. To our knowledge, this is the first case where autologous PBSC have been used to successfully treat a patient with severe aplastic anemia.
